Metsera, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Metsera, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Metsera, Inc. do? Business model and key facts
Get the full picture of Metsera, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 93
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
Stocks related to Metsera, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Metsera, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Metsera, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
